Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function

Precise control of protein function in living cells is essential for engineering programmable biological systems and therapeutic applications. However, most current strategies act indirectly by altering protein stability, localization, or proximity rather than directly modulating binding activity. Here we present VIPbodies, nanobodies engineered with self-cleaving viral proteases that convert protease inhibition into drug-dependent antigen recognition. Using anti-mCherry nanobodies as prototypes, we create variants responsive to orthogonal viral protease–inhibitor pairs and extend the design to diverse nanobody scaffolds. Each VIPbody functions independently within the same cell, enabling multiplexed regulation of distinct targets. When incorporated into transcriptional circuits, VIPbodies mediate drug-tunable gene expression and execute all six canonical Boolean logic operations, providing a compact framework for programmable cellular computation. Beyond gene regulation, VIPbody circuits mediate bidirectional control of pyroptosis and selectively activate apoptotic or pyroptotic programs via caspase coupling, thereby enabling chemogenetic control of protein function and cell fate. Precise control of protein function in living cells is essential for engineering programmable biological systems. Here the authors present VIPbodies, nanobodies engineered with self-cleaving viral proteases that convert protease inhibition into drug-dependent antigen recognition.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-07-30
DOI
https://doi.org/10.1038/s41467-026-76122-1
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function

Mingguang Cui, Yun Huang, Yubin Zhou, Xiaoxuan Liu et al.
Nature Communications
Monoclonal and Polyclonal Antibodies Research
article

Engineering viral protease-operated nanobodies for programmable and orthogonal control of protein function

Mingguang Cui, Yun Huang, Yubin Zhou, Xiaoxuan Liu, Tianlu Wang, Tien‐Hung Lan, Brendan McKee, Tatsuki Nonomura, Rui Wang
article en

Abstract

Precise control of protein function in living cells is essential for engineering programmable biological systems and therapeutic applications. However, most current strategies act indirectly by altering protein stability, localization, or proximity rather than directly modulating binding activity. Here we present VIPbodies, nanobodies engineered with self-cleaving viral proteases that convert protease inhibition into drug-dependent antigen recognition. Using anti-mCherry nanobodies as prototypes, we create variants responsive to orthogonal viral protease–inhibitor pairs and extend the design to diverse nanobody scaffolds. Each VIPbody functions independently within the same cell, enabling multiplexed regulation of distinct targets. When incorporated into transcriptional circuits, VIPbodies mediate drug-tunable gene expression and execute all six canonical Boolean logic operations, providing a compact framework for programmable cellular computation. Beyond gene regulation, VIPbody circuits mediate bidirectional control of pyroptosis and selectively activate apoptotic or pyroptotic programs via caspase coupling, thereby enabling chemogenetic control of protein function and cell fate. Precise control of protein function in living cells is essential for engineering programmable biological systems. Here the authors present VIPbodies, nanobodies engineered with self-cleaving viral proteases that convert protease inhibition into drug-dependent antigen recognition.

Nature Communications
Prevention Institute (US), Texas A&M University (US)
Welch Foundation, Cancer Prevention and Research Institute of Texas, Leukemia and Lymphoma Society, National Institute of General Medical Sciences
Openalex Percentile: Top 9%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.